Every material Form 8-K Akebia Therapeutics, Inc. has filed with the SEC since October 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Akebia Therapeutics reported third-quarter 2026 results on November 5, 2026. Total revenues fell to $36.9 million from $58.8 million a year earlier, and the company posted a net loss of $14.4 million compared with net income of $0.5 million, mainly due to lower Auryxia sales. Vafseo patient count rose to about 11,500, but Vafseo revenue was pressured by a customer inventory reduction.
Auryxia net product revenues were $20.0 million, down from $42.5 million in Q3 2025; the company expects Auryxia revenues to decline in 2026.
Vafseo net product revenues were $14.8 million, compared with $14.3 million in Q3 2025.
Net loss per share was $0.05, compared with $0.00 per share in net income a year earlier; results include a $1.3 million restructuring charge.
Cash and cash equivalents were $159.3 million at September 30, 2026, and the company plans to refinance its senior secured term loan facility.
Akebia Therapeutics received a Nasdaq deficiency letter on October 21, 2026, because its common stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing, and the company has until April 19, 2027 to regain compliance, but it may face delisting if it does not.
Nasdaq notice received October 21, 2026 for closing bid price below $1.00 over 30 consecutive business days
Initial compliance period runs 180 calendar days, until April 19, 2027
Regaining compliance requires at least $1.00 closing bid for 10 consecutive business days; a second 180-day period may be possible
Company says it may consider a reverse stock split, but cannot assure it will regain compliance
Akebia Therapeutics said its Senior Vice President and Chief Commercial Officer, Nicholas Grund, will resign effective November 6, 2026, for personal reasons. Under a consulting agreement, he will advise the company until April 30, 2027, and be paid an hourly rate.
Nicholas Grund notified the company of his resignation on October 7, 2026.
Resignation takes effect November 6, 2026.
Consulting Period runs until April 30, 2027; either side can end it early with notice (10 days for the company, 30 days for Mr. Grund).
The filing does not state a replacement for the chief commercial officer role.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Akebia Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →